Cover Image
市場調查報告書

腦膜炎疫苗:疾病的預測與市場分析

Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2025

出版商 Datamonitor Healthcare 商品編碼 594584
出版日期 內容資訊 英文 202 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腦膜炎疫苗:疾病的預測與市場分析 Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2025
出版日期: 2017年11月15日 內容資訊: 英文 202 Pages
簡介

腦膜炎的病因有各種細菌、疫苗,美國腦膜炎菌 (腦膜炎雙球菌) ,不論幼兒、成人是最大的要素。到目前為止腦膜炎的亞種發現有13種,其中的前5名 (A、B、C、Y、W-135) 佔著患者的90%。

本報告提供腦膜炎疫苗的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,依據過去的相關分析的成果,疾病概要和背景情況,現在/未來的代表性治療藥,全球整體、主要國家的市場趨勢預測,主要產品的簡介,目前臨床實驗的進展等的相關調查。

未來預測:腦膜炎疫苗

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義
  • 美國市場的預測
  • 法國市場預測
  • 德國市場預測
  • 義大利市場預測
  • 西班牙市場預測
  • 英國市場預測
  • KOL (Key Opinion Leader)的分析

已上市醫藥品:腦膜炎疫苗

  • 摘要整理
  • 產品概要
  • 產品簡介:BEXSERO
  • 產品簡介:MENACTRA
  • 產品簡介:MENVEO
  • 產品簡介:NIMENRIX
  • 產品簡介:TRUMENBA

開發中產品:腦膜炎疫苗

  • 摘要整理
  • 臨床實驗開發平台概要
  • 產品簡介 (最後階段):MEN QUAD TT
  • 產品簡介 (最後階段):MENABCW-135Y
目錄
Product Code: DMKC 10644

DISEASE OVERVIEW:

Meningitis is an infection of the meninges, the membranes surrounding the brain and spinal cord. It can be caused by a number of different viral and bacterial pathogens including Haemophilus influenzae b (Hib) and Streptococcus pneumoniae. However, in the US, Neisseria meningitidis is the most common cause of bacterial meningitis in infants and young children, as well as one of the most important causes in adults. There are 13 known serotypes of meningococcal disease, of which five (A, B, C, Y, and W-135) account for 90% of the global disease burden.

MARKET SNAPSHOT:

  • Continued uptake of MenB vaccines and GlaxoSmithKline's pentavalent vaccine launch from 2021 will drive market growth.
  • Cost-effectiveness concerns and scarcity of real-world effectiveness data are key resistors of uptake for MenB vaccines.
  • Pipeline vaccines with broader serotype protection and novel approaches are positioned to replace marketed products.

TABLE OF CONTENTS

FORECAST: MENINGOCOCCAL VACCINES (Published on 15 November 2017)

  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION
  • US MARKET FORECAST
  • FRANCE MARKET FORECAST
  • GERMANY MARKET FORECAST
  • ITALY MARKET FORECAST
  • SPAIN MARKET FORECAST
  • UK MARKET FORECAST
  • KEY OPINION LEADER RESEARCH

MARKETED DRUGS: MENINGOCOCCAL VACCINES (Published on 15 November 2017)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: BEXSERO
  • PRODUCT PROFILE: MENACTRA
  • PRODUCT PROFILE: MENVEO
  • PRODUCT PROFILE: NIMENRIX
  • PRODUCT PROFILE: TRUMENBA

PIPELINE: MENINGOCOCCAL VACCINES (Published on 15 November 2017)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): MEN QUAD TT
  • PRODUCT PROFILE (LATE STAGE): MENABCW-135Y

LIST OF FIGURES

  • Figure 1: Meningococcal vaccines market value across the US and five major EU markets, by country, 2016-25
  • Figure 2: Total sales of meningococcal vaccines in the US, by risk group, 2016-25
  • Figure 3: Total sales of MenB vaccines across the US and five major EU markets, by country, 2016-25
  • Figure 4: Total sales of meningococcal vaccines across the US and five major EU markets, by class, 2016-25
  • Figure 5: Patient-based forecasting methodology for meningococcal vaccines
  • Figure 6: Price sources and calculations in the EU, by country
  • Figure 7: Total sales of meningococcal vaccines in the US, by risk group, 2016-25
  • Figure 8: Total sales of meningococcal vaccines in the US, by class, 2016-25
  • Figure 9: Meningococcal vaccination coverage in the US, by risk group, 2016-25
  • Figure 10: Total sales of meningococcal vaccines in France, by class, 2016-25
  • Figure 11: Meningococcal vaccination coverage in France, by risk group, 2016-25
  • Figure 12: Total sales of meningococcal vaccines in Germany, by class, 2016-25
  • Figure 13: Meningococcal vaccination coverage in Germany, by risk group, 2016-25
  • Figure 14: Total sales of meningococcal vaccines in Italy, by class, 2016-25
  • Figure 15: Meningococcal vaccination coverage in Italy, by risk group, 2016-25
  • Figure 16: Total sales of meningococcal vaccines in Spain, by class, 2016-25
  • Figure 17: Meningococcal vaccination coverage in Spain, by risk group, 2016-25
  • Figure 18: Total sales of meningococcal vaccines in the UK, by class, 2016-25
  • Figure 19: Meningococcal vaccination coverage in the UK, by risk group, 2016-25
  • Figure 20: Bexsero for meningococcal disease - SWOT analysis
  • Figure 21: Menactra for meningococcal disease - SWOT analysis
  • Figure 22: Menveo for meningococcal disease - SWOT analysis
  • Figure 23: Nimenrix for meningococcal disease - SWOT analysis
  • Figure 24: Trumenba for meningococcal disease - SWOT analysis
  • Figure 25: Men Quad TT for meningococcal vaccination - SWOT analysis
  • Figure 26: MenABCW-135Y for meningococcal vaccination - SWOT analysis

LIST OF TABLES

  • Table 1: Meningococcal vaccines market value across the US and five major EU markets, by country ($m), 2016-25
  • Table 2: Total sales of meningococcal vaccines in the US, by risk group ($m), 2016-25
  • Table 3: Total sales of MenB vaccines across the US and five major EU markets, by country ($m), 2016-25
  • Table 4: Total sales of meningococcal vaccines across the US and five major EU markets, by class ($m), 2016-25
  • Table 5: Recommendations for meningococcal vaccination by national authorities, 2017
  • Table 6: Total sales of meningococcal vaccines in the US, by risk group ($m), 2016-25
  • Table 7: Total sales of meningococcal vaccines in the US, by class ($m), 2016-25
  • Table 8: US meningococcal vaccines market forecast, 2016-25
  • Table 9: US meningococcal vaccination coverage rates in recommended risk groups, 2016-25
  • Table 10: Total sales of meningococcal vaccines in France, by class ($m), 2016-25
  • Table 11: France meningococcal vaccines market forecast, 2016-25
  • Table 12: France meningococcal vaccination coverage rates in recommended risk groups, 2016-25
  • Table 13: Total sales of meningococcal vaccines in Germany, by class ($m), 2016-25
  • Table 14: Germany meningococcal vaccines market forecast, 2016-25
  • Table 15: Germany meningococcal vaccination coverage rates in recommended risk groups, 2016-25
  • Table 16: Total sales of meningococcal vaccines in Italy, by class ($m), 2016-25
  • Table 17: Italy meningococcal vaccines market forecast, 2016-25
  • Table 18: Italy meningococcal vaccination coverage rates in recommended risk groups, 2016-25
  • Table 19: Total sales of meningococcal vaccines in Spain, by class ($m), 2016-25
  • Table 20: Spain meningococcal vaccines market forecast, 2016-25
  • Table 21: Spain meningococcal vaccination coverage rates in recommended risk groups, 2016-25
  • Table 22: Total sales of meningococcal vaccines in the UK, by class ($m), 2016-25
  • Table 23: UK meningococcal vaccines market forecast, 2016-25
  • Table 24: UK meningococcal vaccination coverage rates in recommended risk groups, 2016-25
  • Table 25: Key marketed vaccines for meningococcal disease
  • Table 26: Bexsero drug profile
  • Table 27: Bexsero pivotal trial data in meningococcal vaccination
  • Table 28: Bexsero late-phase trial data in meningococcal vaccination
  • Table 29: Bexsero ongoing late-phase trials in meningococcal vaccination
  • Table 30: Menactra drug profile
  • Table 31: Menactra pivotal trial data in meningococcal vaccination
  • Table 32: Menveo drug profile
  • Table 33: Menveo pivotal trial data in meningococcal vaccination
  • Table 34: Menveo pivotal trial data in meningococcal vaccination
  • Table 35: Menveo ongoing late-phase trials in meningococcal vaccination
  • Table 36: Nimenrix drug profile
  • Table 37: Nimenrix pivotal trial data in meningococcal vaccination
  • Table 38: Nimenrix ongoing late-phase trials in meningococcal vaccination
  • Table 39: Trumenba pivotal trial data in meningococcal vaccination
  • Table 40: Trumenba late-phase trial data in meningococcal vaccination
  • Table 41: Trumenba ongoing trial data in meningococcal vaccination
  • Table 42: Phase III pipeline products in development for meningococcal vaccination
  • Table 43: Men Quad TT drug profile
  • Table 44: Men Quad TT Phase III trials in meningococcal vaccination
  • Table 45: Men Quad TT completed Phase II studies in meningococcal vaccination
  • Table 46: MenABCW-135Y drug profile
  • Table 47: MenABCW-135Y Phase II data in meningococcal vaccination
  • Table 48: MenABCW-135Y ongoing trial data in meningococcal vaccination
Back to Top